Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3

European Journal of Biochemistry

Volumn 268, Issue 10, 2001, Pages 2960-2968

  Réhault, Sophie ^a   Monget, Philippe ^b   Mazerbourg, Sabine ^b   Tremblay, Roland ^c   Gutman, Ninette ^a   Gauthier, Francis ^a   Moreau, Thierry ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b UMR85 PHYSIOLOGIE DE LA REPRODUCTION ET DES COMPORTEMENTS   (France)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Human kallikreins; IGF binding proteins; Insulin like growth factors; Prostate cancer; Proteolysis

Indexed keywords

GLYCOSAMINOGLYCAN; HEPARIN; KALLIKREIN; LIGAND; PROTEINASE; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5;

ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; TUMOR GROWTH;

BINDING SITES; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LIGANDS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECOMBINANT PROTEINS; TIME FACTORS; TISSUE KALLIKREINS;

EID: 0034824499     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2001.02185.x     Document Type: Article

References (67)

1. Insulin-like growth factors and their binding proteins: Biological actions
2. Identification of insulin-like growth factor-binding protein-2 (IGF-BP-2) and a low molecular weight IGF-BP in human seminal plasma
3. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma
4. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells
5. Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization
6. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture
7. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
8. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
9. Insulin-like growth factor-binding protein proteolysis. An emerging paradigm in insulin-like growth factor physiology
10. Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4
11. The new human kallikrein gene family: Implications in carcinogenesis
12. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate
13. Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid
14. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions
15. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation
16. Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2
17. 2+ and extracellular protease inhibitors
18. The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein
19. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors
20. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein
21. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen
22. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein
23. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator
24. Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3
25. Purification of enzymatically active kallikrein hK2 from human seminal plasma
26. Simple purification procedure for human prostatic kallikrein hK2 in its active form
27. Active-site titration of peptidases
28. Purification of a human prostate specific antigen
29. Proteolytic activity is involved in changes in intrafollicular insulin-like growth factor-binding protein levels during growth and atresia of ovine ovarian follicles
30. Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix
31. Glycosaminoglycans inhibit degradation of insulin-like growth factor- binding protein-5
32. Human fibroblasts secrete a serine protease that cleaves insulin-like growth factor-binding protein-5
33. Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells
34. Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF) -binding proteins (IGFBPs)-3, -5, and -6 inhibit IGFBP-4 degradation
35. Insulin-like growth factor binding protein-4 proteolytic degradation in ovine preovulatory follicles: Studies of underlying mechanisms
36. Insulin-like growth factor binding proteins and their functions
37. Insulin-like growth factor binding protein (IGFBP) proteolysis: Occurrence, identification, role and regulation
38. The cleavage site specificity of human prostate specific antigen for insulin-like growth factor binding protein-3
39. Biochemical analysis of prostate specific antigen-proteolyzed insulin- like growth factor binding protein-3
40. Glycosaminoglycan binding characteristics of the insulin-like growth factor-binding proteins
41. Factors regulating insulin-like growth factor-binding protein-3 binding, processing, and potentiation of insulin-like growth factor action
42. Role of insulin-like growth factor binding proteins in the control of IGF actions
43. Heparin inhibition of insulin-like growth factor-binding protein-3 binding to human fibroblasts and rat glioma cells: Role of heparan sulfate proteoglycans
44. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin
45. Structural investigation of the alpha-1-antichymotrypsin: Prostate-specific antigen complex by comparative model building
46. Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3
47. Mechanism by which heparin proteoglycan modulates mast cell chymase activity
48. Proteoglycans: Master regulators of molecular encounter?
49. Inflammation-related neutrophil proteases, cathepsin G and elastase, function as insulin-like growth factor binding protein proteases
50. Proteolysis of insulin-like growth factors (IGF) and IGF binding proteins by cathepsin D
51. IGFBP-3 proteolysis by plasmin, thrombin, serum: Heparin binding, IGF binding, and structure of fragments
52. 7S nerve growth factor is an insulin-like growth factor-binding protein protease
53. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures
54. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): Implications for IGF and IGF-I receptor interactions
55. Structure-function analysis of the human insulin-like growth factor binding protein-4
56. Insulin and IGF binding by IGFBP-3 fragments derived from proteolysis, baculovirus expression and normal human urine
57. Partial IGF affinity of circulating N- and C-terminal fragments of human insulin-like growth factor binding protein-4 (IGFBP-4) and the disulfide bonding pattern of the C-terminal IGFBP-4 domain
58. The insulin-like growth factor (IGF) binding site of bovine insulin-like growth factor binding protein-2 (bIGFBP-2) probed by iodination
59. Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain
60. A 3-dimensional model for the insulin-like growth factor binding proteins (IGFBPs); supporting evidence using the structural determinants of the IGF binding site on IGFBP-3
61. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate
62. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen
63. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
64. Endothelium-derived factors as paracrine mediators of prostate cancer progression
65. Human prostate cancer model: Roles of growth factors and extracellular matrices
66. Insulin-like growth factor binding proteins in bone cell regulation
67. Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures: Regulation by prostaglandin E2, growth hormone, and the insulin-like growth factors